The proposed mechanism of action described in the claim that 5G millimeter waves can generate SARS-CoV-2 in human cells violates fundamental principles of biology. Scientific evidence does not support a causal relationship between 5G and COVID-19. Many of the regions with the highest COVID-19 infection rates, such as Brazil, do not have 5G coverage, providing further evidence that 5G is not associated with the pandemic.
FULL CLAIM: 5G generates coronavirus in human skin cells
Scientists from 4 different Swiss universities describe how adhesion molecules activate autoaggressive immune cells and drive their infiltration in the nervous system in a model of multiple sclerosis.
Click to read the paper published in Frontiers in Immunology: https://fro.ntiers.in/tp1U
In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), myelin-specific T cells are activated in the periphery and differentiate in T helper (Th) 1 and Th17 effector cells, which cross the blood-brain barrier (BBB) to reach the central nervous system (CNS), where they induce neuroinflammation. Here, we explored the role of intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 in the activation of naïve myelin-specific T cells and in the subsequent migration of differentiated encephalitogenic Th1 and Th17 cells across the BBB in vitro and in vivo. While on antigen-presenting cells ICAM-1, but not ICAM-2 was required for the activation of naïve CD4+ T cells, endothelial ICAM-1 and ICAM-2 mediated both Th1 and Th17 cell migration across the BBB. ICAM-1/-2-deficient mice developed ameliorated typical and atypical EAE transferred by encephalitogenic Th1 and Th17 cells, respectively. Our study underscores important yet cell-specific contributions for ICAM-1 and ICAM-2 in EAE pathogenesis.
Multiple sclerosis (MS) is considered an autoimmune inflammatory demyelinating disease of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE), a prototypic animal model for MS, mimics many aspects of the acute inflammatory phase of the human disease (1). In EAE, naïve myelin-reactive CD4+ T cells are activated and differentiated in peripheral lymphoid tissue into encephalitogenic Th1 or Th17 cells, which travel in the blood circulation to the CNS. After crossing the blood-brain barrier (BBB) they next infiltrate in the CNS parenchyma, leading to clinical manifestation of the disease (2). EAE can be actively induced by immunization with CNS myelin antigens emulsified in complete Freund’s adjuvant (aEAE) or by injection of myelin-reactive CD4+ T cells into syngeneic naïve recipients (tEAE) (3, 4).
Activation of naïve CD4+ T cells during aEAE occurs in the draining peripheral lymph nodes (dLNs), where T cells recognize their cognate antigen (Ag) on antigen-presenting cells (APCs) forming periodic contacts between the T-cell receptor (TCR) and the myelin oligodendrocyte glycoprotein (MOG)aa35−55 peptide loaded major histocompatibility complex (pMHC) on the APCs, referred to as the immunological synapse (IS) (5, 6). The fate of naïve T cells is determined within hours after Ag exposure by interacting with APCs in LN. The interaction between the integrin lymphocyte function associated antigen-1 (LFA-1) on the T cells and its ligand intercellular adhesion molecule-1 (ICAM-1) on the APCs is suggested to be involved in modulating the IS. However, APCs additionally express ICAM-2, an alternate ligand of LFA-1.
COSTA MESA, Calif. – Health experts say around half of American adults are overweight or obese. While excessive body weight is linked to a number of serious health conditions, including diabetes and heart disease, a new study reveals it can also reduce blood flow to the brain. Researchers warn this can put overweight individuals at great risk for Alzheimer’s disease.
The study examines brain blood flow in 17,721 adults between 18 and 94. To do this, researchers use a brain imaging technique known as single photon emission computed tomography (SPECT).
SPECT is a technique in which doctors inject a radioactive tracer into a patient’s blood and then use a special camera to look at the flow of blood. Participants were then split into five categories: underweight, normal weight, overweight, obese, and morbidly obese — to examine blood flow in each of their brains. The brain scan data reveals lower blood flow across virtually all brain regions as body weight increases.
While satellite imaging lets researchers observe the outer life of plankton populations, the complex genetics in microscopic marine life have made looking inward more challenging. According to a new study published in Nature Methods, researchers from the University of East Anglia were able to deliver and express foreign DNA in 13 species that have never before transformed. They were also able to evaluate the potential cause of non-transformation in 17 other species; in turn, laying the foundation for an expanded understanding of genomes discovered in plankton.
The sheer variety of plankton potential — from antibacterial compounds to antiviral and antifungal solutions — makes this a worthwhile endeavor. If scientists can create reliable methods to modify phytoplankton, it should be possible to reduce their toxic impact, better control their bloom cycle and even increase the photosynthetic output — all critical in the fight to keep our oceans blue and our terra firma green.
As noted by Science Magainze, the international research team used a variety of methods to modify plankton DNA. For some species, shooting tiny gold or tungsten particles covered with DNA through cell walls produced the best result. For others, jolts of electricity made cell walls “leaky” and allowed new DNA to seep through. Specific protist successes included modification of a fish-killing toxic plankton species, and one that infects both mollusks and amphibians. While these discoveries don’t present a complete understanding of the genetics in microscopic marine life, they provide a key testing protocol: By modifying genetic structure and then observing how plankton react, teams could uncover ways to boost antibiotic resistance or lower infectious impact. According to lead UK study author Thomas Mock, “These insights will improve our understanding about their role in the oceans, and they are invaluable for biotechnological applications such as building factories for biofuel or the production of bioactive compounds.”
What is CTAP?
FDA has created a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP)
.
The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful.
In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19.
One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.
The FDA issued an E… See More
The nitazoxanide plus atazanavir for COVID-19 study — full text view.
Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.
In this pilot study, 98 COVID-19 patients will be recruited into two group. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days.
Topic: guest: dan elton phd, staff scientist at national institute of health, USA.
Topic: Application of AI to medical imaging Guest: Dan Elton PhD, Staff Scientist at National Institute of Health, USA.
Keith Comito, president of Life Extension Advocacy Foundation, joins me for a discussion to preview the 2020 Eding Age Related Diseases conference, to be held online, August 20–21, 2020. Go HERE to register for the conference, and use discount code SeekingDelphiEARD
You can subscribe to Seeking Delphi™ on Apple podcasts, PlayerFM, MyTuner, Listen Notes, and YouTube. You can also follow us on twitter @Seeking_Delphi and Facebook.